Abstract
In reply Drs Loewenstein and Lazar are concerned that patients were not properly selected for our study. They believe that patients who do not respond to monotherapy should not be defined as requiring two medications until the first one is withdrawn and a replacement is tried. In clinical practice, it is very rare to encounter a patient who does not respond to timolol or to pilocarpine eye drops. If such a patient was to be treated rationally, then the ineffective first drug would be withdrawn and a second drug tried. We have not seen any published argument that shows that 2% or 4% pilocarpine three or four times daily would be more effective than 0.25% or 0.5% timolol twice daily. Although some long-term timolol users demonstrate a slow upward drift of the intraocular pressure after several months of the start of the therapy 1 and higher pilocarpine concentrations—seldom used in
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
